Fate delivers, up to a point
The first human data from the Car-NK project FT596 are impressive – but not impressive enough for a company worth $9bn.
Fate looks to justify its $9bn valuation
The glacial development of Fate’s anti-CD19 Car-NK therapy FT596 could yield real data at last.
Sigilon hold hurts ahead of key haemophilia meeting
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
Asco 2021 – off-the-shelf cell therapy inches towards reality
After years of waiting, courtesy of Allogene investors at last have an allogeneic Car-T dataset comparable with autologous therapies.
Asco 2021 – Adaptimmune’s T-cell receptors see a route to market
The registrational Spearhead-1 trial of afami-cel backs up the efficacy seen in phase 1, without some of the related toxicities.
Precision’s itinerant Car-T cells go on another journey
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
